The present invention relates to a mutant microorganism having the ability to produce 5-aminolevulinic acid, and more particularly, to a mutant microorganism having the ability to produce 5-aminolevulinic acid wherein a glutamyl-tRNA reductase-encoding gene is introduced in a glutamic acid-producing microorganism, and to a method for producing 5-aminolevulinic acid using the same. According to the present invention, 5-aminolevulinic acid that is useful in the medical or agricultural field can be produced in a significantly higher yield than that of conventional production methods.

The disclosure discloses a method for increasing the intracellular heme content of Escherichia coli and belongs to the field of metabolic engineering. In the disclosure, in E. coli, the gene mscS encoding a small conductance mechanically sensitive ion channel protein is knocked out, the gene aroG encoding 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase is knocked out, or the gene hemA encoding glutamyl-tRNA reductase is overexpressed. The constructed recombinant strain is cultured in an LB culture medium, and the heme content can reach 47.6 μmol.Math.L.sup.−1, which is significantly higher than that of a control strain. The recombinant strain has the value of wide application.

The present invention relates to a recombinant microorganism having an enhanced ability to produce heme, coproporphyrin III (Copro III), and uroporphyrin III (Uro III), and a method for producing heme, coproporphyrin III, and uroporphyrin III using same. When using a recombinant microorganism incorporating a gene that codes glutamyl-tRNA reductase (HemA), glutamate-1-semialdehyde aminotransferase (HemL), and diphtheria toxin repressor (DtxR), which is a transcription factor capable of inducing the expression of genes related to heme metabolic pathways, porphyrin-based structures can be produced at high yield, and thus the method is economic.

The present invention relates to a microorganism variant having the ability to extracellularly produce heme, and more particularly to a metabolically engineered microorganism variant having the ability to extracellularly produce heme and a method of producing heme using the same. According to the present invention, heme, an organometallic compound which is increasingly used as a health food or food supplement for the treatment of porphyria, can be extracellularly secreted and produced in high yield using the microorganism variant, but not conventional chemical synthesis or enzymatic synthesis.

The invention relates to a genetically modified prokaryotic cell capable of improved iron-sulfur cluster delivery, characterized by a modified gene encoding a mutant Iron Sulfur Cluster Regulator (IscR) and one or more transgenes or upregulated endogenous genes encoding iron-sulfur (Fe—S) cluster polypeptides or proteins that catalyze complex radical-mediated molecular rearrangements, electron transfer, radical or non-redox reactions, sulfur donation or perform regulatory functions. The prokaryotic cells are characterized by enhanced activity of these iron-sulfur (Fe—S) cluster polypeptides, enhancing their respective functional capacity, and facilitating enhanced yields of compounds in free and protein-bound forms, including heme, hemoproteins, tetrapyrroles, B vitamins, amino acids, δ-aminolevulinic acid, biofuels, isoprenoids, pyrroloquinoline quinone, ammonia, indigo, or their precursors, whose biosynthesis depends on their activity. The invention further relates to a method for producing said compounds or their precursors using the genetically modified prokaryotic cell of the invention, and the use of the genetically modified prokaryotic cell.

Disclosed are recombinant strain of a genus Corynebacterium capable of producing biliverdin IX-alpha (IXα) and a method of producing biliverdin IX-alpha using the same. The recombinant strain is capable of synthesizing biliverdin IX-alpha in an environmentally friendly manner using only glucose without the addition of any nitrogen source, thus replacing the synthesis of biliverdin IX-alpha through chemical treatment, which is a conventional synthetic method causing environmental pollution problems.

Disclosed are recombinant strain of a genus Corynebacterium capable of producing biliverdin IX-alpha (IX) and a method of producing biliverdin IX-alpha using the same. The recombinant strain is capable of synthesizing biliverdin IX-alpha in an environmentally friendly manner using only glucose without the addition of any nitrogen source, thus replacing the synthesis of biliverdin IX-alpha through chemical treatment, which is a conventional synthetic method causing environmental pollution problems.

The present invention relates to a recombinant microorganism having an enhanced ability to produce heme, coproporphyrin III (Copro III), and uroporphyrin III (Uro III), and a method for producing heme, coproporphyrin III, and uroporphyrin III using same. When using a recombinant microorganism incorporating a gene that codes glutamyl-tRNA reductase (HemA), glutamate-1-semialdehyde aminotransferase (HemL), and diphtheria toxin repressor (DtxR), which is a transcription factor capable of inducing the expression of genes related to heme metabolic pathways, porphyrin-based structures can be produced at high yield, and thus the method is economic.

The present invention relates to a microorganism variant having the ability to extracellularly produce heme, and more particularly to a metabolically engineered microorganism variant having the ability to extracellularly produce heme and a method of producing heme using the same. According to the present invention, heme, an organometallic compound which is increasingly used as a health food or food supplement for the treatment of porphyria, can be extracellularly secreted and produced in high yield using the microorganism variant, but not conventional chemical synthesis or enzymatic synthesis.

The present invention relates to a mutant microorganism having the ability to produce 5-aminolevulinic acid, and more particularly, to a mutant microorganism having the ability to produce 5-aminolevulinic acid wherein a glutamyl-tRNA reductase-encoding gene is introduced in a glutamic acid-producing microorganism, and to a method for producing 5-aminolevulinic acid using the same. According to the present invention, 5-aminolevulinic acid that is useful in the medical or agricultural field can be produced in a significantly higher yield than that of conventional production methods.